CN100382824C - Chinese traditional medicine for treating chronic hepatitis, and preparation method - Google Patents
Chinese traditional medicine for treating chronic hepatitis, and preparation method Download PDFInfo
- Publication number
- CN100382824C CN100382824C CNB2006100759135A CN200610075913A CN100382824C CN 100382824 C CN100382824 C CN 100382824C CN B2006100759135 A CNB2006100759135 A CN B2006100759135A CN 200610075913 A CN200610075913 A CN 200610075913A CN 100382824 C CN100382824 C CN 100382824C
- Authority
- CN
- China
- Prior art keywords
- radix
- fructus
- schisandrae chinensis
- fructus schisandrae
- poria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention provides a Chinese medicine for treating chronic hepatitis, which is composed of bupleurum root, fructus, white peony root, red sage root, astragalus root, etc. The preparation of the present invention can be any acceptable oral medicine on pharmacy. The present invention also provides a preparation method for the Chinese medicine, particularly a preparation method for medicine granules, tablets, capsules and pills. By the verification of pharmacodynamic experiments, the Chinese medicine of the present invention has an obvious treating effect on the chronic hepatitis, is superior to other similar products obviously and has the advantages of convenient use and small side effect.
Description
Technical field
The present invention relates to field of traditional Chinese, in particular to a kind of Chinese medicine for the treatment of chronic hepatitis and preparation method thereof.
Background technology
Viral hepatitis is a Notifiable disease, has that infectiousness is strong, complicated, popular wide general, the sickness rate in route of transmission is than characteristics such as height.Especially hepatitis B is classified as the 9th that causes the global cause of death by World Health Organization (WHO).The general whole world of hepatitis B virus carriers has 3.5 hundred million, and China has 1.3 hundred million, accounts for the 10%-15% of whole population, and the hepatitis C whole world has 1.7 hundred million, and our country has 38,000,000, accounts for 20% of the whole world again.Modern medicine has been done a large amount of research from epidemiology, molecular biology aspect to viral hepatitis, but does not still have important breakthrough in the treatment.Antiviral agent such as interferon, vidarabine, acycloguanosine, the medicine high price is expensive, and side effect is more, be difficult to apply, and Chinese medicine has better or certain curative effect, and safety, toxic and side effects is little.
Viral hepatitis is from clinical five types that are divided into, and acute hepatitis, chronic hepatitis, hepatitis gravis, silt gallbladder hepatitis also have posthepatitic cirrhosis.The acute hepatitis protracted course of disease, the course of disease surpasses person's half a year, is called chronic hepatitis.Pathological change according to its symptom and sign and liver is divided into chronic persistent hepatitis and chronic active hepatitis.Chronic hepatitis causes liver cirrhosis and hepatocarcinoma again easily, is a kind of disease of serious harm people ' s health.Chronic hepatitis is the doctor trained in Western medicine name of disease, can be by virus, medicine, due to the Nutrition and Metabolism Different types of etiopathogenises, the pathogeny more complicated, from traditional Chinese medical science angle often say by damp and hot pathogenic factor pent up puzzled, with the passing of time injure internal organs and QI and blood, cause variation of decline property and dysfunctional to change.The variation of decline property can have differences such as the deficiency of YIN, yang deficiency, the deficiency of vital energy, blood deficiency regulating YIN and YANG two void, QI and blood deficiency.The dysfunctional variation then mostly is disorder of QI and blood (as stagnation of QI due to depression of the liver, qi depression to blood stasis), incoordination between the spleen and stomach, disarmony between the heart and kidney etc.
Hepatitis mid-term, damp and hot malicious heresy is reluctant to leave, and healthy energy is empty, forms good and evil and hands over the state of striving.Outstanding behaviours is a stagnation of liver-QI with deficiency of the spleen, and wet resistance sun is held back.The liver soothing and the spleen invigorating is worked as in treatment, and removing dampness activates yang.The medicine that various these type of diseases of treatment are arranged on the market, but effect is unsatisfactory.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine for the treatment of chronic hepatitis, evident in efficacy, the taking convenience of this Chinese medicine, side effect is little.
The present invention also provides this preparation method of Chinese medicine.
Chinese medicine of the present invention activates yang based on liver-smoothing, qi-regulating resolving depression, invigorating the spleen and benefiting QI, is equipped with dispersing the stagnated pathogen with pungent drugs and lowering the adverse QI with bitter drugs, the stagnant product of dampness removing heat clearing awayization, Folium Citri tangerinae, Radix Bupleuri, Fructus Aurantii liver-smoothing, qi-regulating resolving depression in the medicine of the present invention; Radix Salviae Miltiorrhizae, Radix Paeoniae Alba nourishing blood to suppress the hyperactive liver; Fructus Trichosanthis, the Rhizoma Pinelliae, Rhizoma Coptidis open the breast painful abdominal mass that disappears reduces phlegm; The Radix Astragali, Radix Codonopsis, Radix Et Caulis Acanthopanacis Senticosi, Ramulus Cinnamomi invigorating the spleen and benefiting QI activate yang; The Fructus Schisandrae Chinensis dispersing the stagnated pathogen with pungent drugs and lowering the adverse QI with bitter drugs; Joining Semen Cassiae, Poria, Fructus Crataegi dampness removing heat clearing away eliminate indigestion stagnates; Full side plays the merit that the liver soothing and the spleen invigorating, removing dampness activate yang altogether,, mends and oiliness temperature and mend dry with strengthening vital QI to eliminate pathogenic factors.To the stagnation of liver-QI with deficiency of the spleen of chronic hepatitis, the wet resistance sun person of holding back is the most suitable.
Medicine of the present invention can not only recover liver function, suppresses hepatitis B virus duplication, and can improve effectively and eliminates patient because of stagnation of liver-QI with deficiency of the spleen, and wet resistance sun is held back the symptom that is occurred, the advantage and the characteristic of embodiment differentiation of tcm.
Chinese medicine of the present invention is prepared from by acceptable auxiliary on following weight parts proportion raw material and the pharmaceutics:
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 10～30 Fructus Aurantiis 10～30 Radix Paeoniae Albas 20～40 Folium Citri tangerinae 10～30
Radix Salviae Miltiorrhizae 20～40 Radixs Astragali 25～55 Radix Codonopsis 15～35 Ramulus Cinnamomi 5～15
Poria 20～40 Radix Et Caulis Acanthopanacis Senticosis 20～40 Fructus Trichosanthis 20～40 Rhizoma Pinelliae Preparatum 16～32
Rhizoma Coptidis 5～15 Semen Cassiaes 20～40 Fructus Crataegis 20～40 Fructus Schisandrae Chinensis 10～30.
The weight portion proportion optimization of above-mentioned raw materials:
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 13.33～26.67 Fructus Aurantiis 13.33～26.67 Radix Paeoniae Albas 20～40 Folium Citri tangerinae 13.33～26.67
Radix Salviae Miltiorrhizae 20～40 Radixs Astragali 26.67～53.33 Radix Codonopsis 16～32 Ramulus Cinnamomi 6.67～13.33
Poria 20～40 Radix Et Caulis Acanthopanacis Senticosis 20～40 Fructus Trichosanthis 20～40 Rhizoma Pinelliae Preparatum 16～32
Rhizoma Coptidis 6.67～13.33 Semen Cassiaes 20～40 Fructus Crataegis 20～40 Fructus Schisandrae Chinensis 13.33～26.67.
The weight portion proportioning of above-mentioned raw materials is also preferred:
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 15～25 Fructus Aurantiis 15～25 Radix Paeoniae Albas 25～35 Folium Citri tangerinae 15～25
Radix Salviae Miltiorrhizae 25～35 Radixs Astragali 30～50 Radix Codonopsis 20～30 Ramulus Cinnamomi 8～12
Poria 15～35 Radix Et Caulis Acanthopanacis Senticosis 25～35 Fructus Trichosanthis 25～35 Rhizoma Pinelliae Preparatum 20～30
Rhizoma Coptidis 8～12 Semen Cassiaes 25～35 Fructus Crataegis 25～35 Fructus Schisandrae Chinensis 15～25.
The weight portion proportioning of above-mentioned raw materials is also preferred:
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 20 Fructus Aurantiis 20 Radix Paeoniae Albas 30 Folium Citri tangerinae 20
Radix Salviae Miltiorrhizae 30 Radixs Astragali 40 Radix Codonopsis 24 Ramulus Cinnamomi 10
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 30 Rhizoma Pinelliae Preparatum 24
Rhizoma Coptidis 10 Semen Cassiaes 30 Fructus Crataegis 30 Fructus Schisandrae Chinensis 20.
The weight portion proportioning of above-mentioned raw materials is also preferred:
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 10 Fructus Aurantiis 30 Radix Paeoniae Albas 20 Folium Citri tangerinae 15
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 15 Ramulus Cinnamomi 5
Poria 40 Radix Et Caulis Acanthopanacis Senticosis 40 Fructus Trichosanthis 20 Rhizoma Pinelliae Preparatum 30
Rhizoma Coptidis 6 Semen Cassiaes 30 Fructus Crataegis 35 Fructus Schisandrae Chinensis 30.
The weight portion proportioning of above-mentioned raw materials is also preferred:
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 30 Fructus Aurantiis 10 Radix Paeoniae Albas 40 Folium Citri tangerinae 30
Radix Salviae Miltiorrhizae 20 Radixs Astragali 30 Radix Codonopsis 35 Ramulus Cinnamomi 5
Poria 20 Radix Et Caulis Acanthopanacis Senticosis 20 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 15 Semen Cassiaes 20 Fructus Crataegis 20 Fructus Schisandrae Chinensis 10.
The weight portion proportioning of above-mentioned raw materials is also preferred:
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 25 Fructus Aurantiis 20 Chinese herbaceous peonies 25 Folium Citri tangerinae 10
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 20 Ramulus Cinnamomi 15
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 10 Semen Cassiaes 40 Fructus Crataegis 40 Fructus Schisandrae Chinensis 10.
Preparation of the present invention can be prepared into acceptable oral Pharmaceutical dosage forms on any pharmaceutics according to the common process of this area.Preferred particulates agent, pill, hard capsule, soft capsule or tablet.
Adjuvant among the present invention is an acceptable auxiliary on the pharmaceutics, for example starch, lactose, sucrose, dextrin, betacyclodextrin, magnesium stearate, Pulvis Talci, aspartame, cyclamate, stevioside, crosslinked polyethylene pyrrole Lip river alkane ketone, crosslinked poly-carmethose, micropowder silica gel, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, gelatin, Polyethylene Glycol-400, Polyethylene Glycol-6000, glycerol, ethyl hydroxybenzoate, vegetable oil, or hydrogenated vegetable wet goods.
Granule of the present invention can be made by the method for being prepared as follows: above ten Six-elements, and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby.With 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water, and collecting decoction is centrifugal, gets centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merges, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and adjuvant, granulates, and granulate, packing, promptly.
Preparation of the present invention also can be made granule by the method for being prepared as follows:
More than ten Six-elements, Fructus Schisandrae Chinensis is pulverized the back with 60～90% alcohol reflux, extracting solution recovery ethanol is standby.Ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, and qinghuo reagent adds adjuvant, granulates, granulate, packing is promptly.
Tablet of the present invention or dispersible tablet can prepare as follows:
More than ten Six-elements, the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby.With 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water, and collecting decoction is centrifugal, gets centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merges, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and adjuvant, granulates, and tabletting, coating, promptly.
Tablet of the present invention or dispersible tablet can also prepare as follows:
More than ten Six-elements, Fructus Schisandrae Chinensis is pulverized the back with 60～90% alcohol reflux, extracting solution recovery ethanol is standby.Ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, and qinghuo reagent adds adjuvant, granulates, granulate, tabletting, promptly.
Hard capsule of the present invention can prepare as follows:
More than ten Six-elements, the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby.With 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water, and collecting decoction is centrifugal, gets centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merges, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and adjuvant dry or granulation or system piller, capsule charge, promptly.
Preparation of the present invention also can be made hard capsule as follows:
More than ten Six-elements, Fructus Schisandrae Chinensis is pulverized the back with 60～90% alcohol reflux, extracting solution recovery ethanol is standby.Ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds adjuvant granulation or system piller, drying, and capsule charge, promptly.
Preparation of the present invention can be made pill as follows:
Preparation method of Chinese medicine according to claim 10 is characterized in that the preparation method of pill comprises the following steps: above ten Six-elements, and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, and mixing, its coarse powder is standby.With 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water, and collecting decoction is centrifugal, gets centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merges, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and adjuvant, and pill selects ball, packing, promptly.
Preparation of the present invention also can be made pill as follows:
More than ten Six-elements, Fructus Schisandrae Chinensis is pulverized the back with 60～90% alcohol reflux, extracting solution recovery ethanol is standby.Ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, and qinghuo reagent adds adjuvant, and pill selects ball, packing, promptly.
Preparation of the present invention also can be made soft wafer agent as follows:
More than ten Six-elements, Fructus Schisandrae Chinensis is pulverized the back with 60～90% alcohol reflux, extracting solution recovery ethanol is standby.Ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, and drying adds adjuvant, makes soft capsule, promptly.
Fructus Schisandrae Chinensis can be used as following step process in the preparation of the present invention: after the Fructus Schisandrae Chinensis fragmentation, use carbon dioxide supercritical fluid extraction, extracting pressure: 18-25Mpa, temperature: 40-50, time: 2.5-3 hour, separation temperature: 40-50 ℃, pressure: 6Mpa, flow velocity: 47-53kg/h.
Preparation of the present invention indication clinically is the QI invigorating removing dampness, dispersing the stagnated live-QI to relieve the stagnation of QI.All genus stagnation of liver-QI with deficiency of the spleen, wet resistance sun are held back, and card is seen: hypochondriac pain abdominal distention, and feeling of fullness is indigestion and loss of appetite, and body is tired weak, and big loose stool is thin, and pale tongue is dark, and tongue body is swollen or indentation is arranged, thin white fur of tongue or white greasy, deep and stringy pulse or deep and slow etc. all can be taken.Specifically can be used for treating the liver-depression and spleen-insufficiency type chronic hepatitis, chronic gastritis of patient, the relatively hepatitis virus carrier of the deficiency of vital energy, and genus " stagnation of liver-QI with deficiency of the spleen " pattern of syndrome and peptic ulcer, chronic bacillary dysentery, chronic enteritis, coronary heart disease, chronic pulmonary heart disease, psychosis, hyperthyroidism, aural vertigo disease, dysfunctional uterine hemorrhage, infantile dyspepsia, infantile malnutrition, glaucoma etc. after chronic hepatitis stable phase, cirrhotic ascites disappear.
Medicine granule for treating of the present invention is 5～10 gram/bags, during use, and 1～2 bag/time, 3 times/day.
Medicinal tablet of the present invention is 0.4～0.8 gram/sheet, during use, and 4～8 slices/time, 3 times/day.
Medicine hard capsule of the present invention is 0.35～0.65 gram/grain, during use, and 6～10/time, 3 times/day.
Bolus of drug of the present invention is 3～8 gram/bags, during use, and 1～2 bag/time, 3 times/day.
Medicine dispersible tablet of the present invention is 0.4～0.8 gram/sheet, during use, and 4～8 slices/time, 3 times/day.
Medicinal soft capsule of the present invention is 0.3～0.6 gram/grain, during use, and 6～10/time, 3 times/day.
Confirm that through clinical experiment Chinese medicine preparation of the present invention has significant curative effect to chronic hepatitis, and taking convenience, side effect is little.Concrete experimental data is as follows:
The pharmacodynamic experiment data
This tests the granule of used medicine for medicine of the present invention.
One, antagonism mouse carbon tetrachloride lethal effect
Getting Kunming hybridization is white mice, body weight 18～20 grams, male and female half and half, every group 10, totally 12 groups, 1～4 group is the blank group, irritate stomach normal saline 0.4ml/20g Mus body weight every day, continuous irrigation stomach six days, 5～8 groups is the administration group, irritate stomach Chinese medicine granules of the present invention every day, dosage is 4.4g/kg, continuous irrigation stomach six days, 9～12 groups, be administration group (2), identical with administration group dosage, use so that investigate difference.After each group administration 6 was sweet, after the 6th administration 1.5 hours, each organized the various dose that mice group is given 50% carbon tetrachloride Oleum Arachidis hypogaeae semen, and with the median lethal dose(LD 50) of the mouse stomach of measuring carbon tetrachloride, statistics is respectively organized LD
50The difference of value the results are shown in Table 1.
The antagonism of table 1 pair mouse carbon tetrachloride lethal dose
| Group | Dosage | Administration for several times | Carbon tetrachloride LD 50(ml) | P |
| The normal saline group | 20ml/kg | 6 | 4.14±0.17 | |
| The administration group | 4.4g/kg | 6 | 6.9±0.59 | ＜0.01 |
| Administration group (2) | 4.4g/kg | 6 | 6.3±0.21 | ＜0.01 |
Experimental result shows, medicine of the present invention is by the dosage successive administration 6 days of 4.4g/kg every day, and accumulated dose reaches 26.4g/kg, can obviously reduce the toxicity of carbon tetrachloride to mice, increases LD significantly
50Value illustrates that medicine of the present invention has significant antagonism to the lethal effect of mouse carbon tetrachloride, has indicated that carbon tetrachloride hepatic injury is had protective effect.
Two, the influence of liver function
Get the Kunming hybridize mice, body weight 23～25 grams, grouping immediately, every group 10, male and female half and half, dosage gastric infusion every day of pressing 4.4g/kg is once, continuous seven days, last administration 24 lab scales were irritated stomach and are given 3% carbon tetrachloride peanut oil solution and continue administration, respectively at 24 hours, 48 hours, the eye socket vein was got blood, measured serum glutamic pyruvic transminase, thymol turbidity, zinc sulfate turbidity.With the normal saline group, bifendate group and blank group compare simultaneously, and it the results are shown in Table 2.
The influence of table 2 pair carbon tetrachloride hepatic injury 24 lab scale serum glutamic pyruvic transminases
The result shows, medicine of the present invention can reduce significantly by due to the carbon tetrachloride mice glutamate pyruvate transaminase ground raise, it is approaching that the enzyme effect falls in its effect and bifendate ground, falls the enzyme effect and can maintain 24～28 hours.See Table 3.
Give behind the carbon tetrachloride 48 hours and measure thymol turbidity and zinc sulfate turbidity in the serum, the result (sees Table 4, table 5) find out that Chinese medicine of the present invention can reduce thymol turbidity and zinc sulfate turbidity significantly, and bifendate group and carbon tetrachloride group (are normal saline+CCl
4Group) relatively, no significant difference.
The influence of 48 hours serum thymol turbidities of table 4 pair carbon tetrachloride hepatic injury
The influence of 48 hours serum zinc sulfate turbdity of table 5 pair carbon tetrachloride hepatic injury
Three, the downright bad effect of mouse liver cell due to the antagonism carbon tetrachloride
Get 40 of Kunming hybridize mices, male and female half and half, be divided into four groups, every group 10, granule group of the present invention is irritated stomach once by the dosage of 4.4g/kg every day, successive administration seven days, the dosed administration that the bifendate group is pressed 33mg/kg was given 3% carbon tetrachloride peanut oil solution on 8th once a day, continued administration and put to death after 48 hours and get liver, routine is embedding admittedly surely, film-making, microscopy is observed hepatic necrosis cell in four visuals field with every slice, thin piece, inflammatory infiltration cell and fatty become cell number and carry out classification into index, the difference degree between relatively each is organized with nonparametric Ridit analytic process.
Each grade standard:
(-): not seeing in four visuals field has non-viable non-apoptotic cell (other are also same)
(+): 1～3 person is arranged in four visuals field
(++): 4～6 persons are arranged in four visuals field
(+++): 7～9 persons are arranged in four visuals field
(++ ++): 10 above persons are arranged in four visuals field
(++ +++): have in four visuals field large-area, can't the counter
Experimental result sees Table 6,7, and 8
The anti-carbon tetrachloride mouse liver cell of table 6 degree of necrosis
| Degree of necrosis classification group | +++++ | ++++ | +++ | ++ | + | - | Summation |
| Normal saline+CCl 4 | 7 | 0 | 1 | 1 | 0 | 0 | 9 |
| Granule+CCl of the present invention 4 | 1 | 0 | 2 | 3 | 2 | 0 | 8 |
| Bifendate+CCl 4 | 4 | 1 | 0 | 1 | 1 | 2 | 9 |
| Blank | 1 | 2 | 0 | 0 | 4 | 2 | 9 |
The Ridit that compares between group analyzes
| Group Ridit | Normal saline+CCl 4 | Granule+CCl of the present invention 4 | Bifendate+CCl 4 | Blank |
| Average Ridit value | 0.50 | 0.86 | 0.70 | 0.88 |
| The fiducial limit scope | 0.31～0.69 | 0.66～1.06 | 0.51～0.89 | 0.69～1.07 |
| Compare (P) with the carbon tetrachloride group | ＞0.05 | ＞0.05 | ＞0.05 |
The anti-carbon tetrachloride mouse liver cell of table 7 inflammatory infiltration degree
| Cell infiltration grading group | +++++ | ++++ | +++ | ++ | + | - | Summation |
| Normal saline+CCl 4 | 0 | 0 | 0 | 0 | 6 | 3 | 9 |
| Granule+CCl of the present invention 4 | 0 | 0 | 0 | 1 | 3 | 4 | 8 |
| Bifendate+CCl 4 | 0 | 0 | 0 | 2 | 4 | 2 | 9 |
| Blank | 0 | 0 | 0 | 1 | 6 | 2 | 9 |
The Ridit that compares between group analyzes
| Group Ridit | Normal saline+CCl 4 | Granule+CCl of the present invention 4 | Bifendate+CCl 4 | Blank |
| Average Ridit value | 0.50 | 0.61 | 0.48 | 0.63 |
| The fiducial limit scope | 0.31～0.69 | 0.41～0.81 | 0.29～0.67 | 0.44～0.82 |
| Compare (P) with the carbon tetrachloride group | ＞0.05 | ＞0.05 | ＞0.05 |
The anti-carbon tetrachloride mouse liver cell of table 8 fatty becomes concentration to the bone
| Inflammatory cell infiltration classification group | +++++ | ++++ | +++ | ++ | + | - | Summation |
| Normal saline+CCl 4 | 1 | 0 | 3 | 3 | 2 | 0 | 9 |
| Granule+CCl of the present invention 4 | 0 | 0 | 1 | 4 | 2 | 1 | 8 |
| Bifendate+CCl 4 | 4 | 2 | 0 | 0 | 1 | 2 | 9 |
| Blank | 0 | 0 | 0 | 0 | 0 | 9 | 9 |
The Ridit that compares between group analyzes
| Group Ridit | Normal saline+CCl 4 | Granule+CCl of the present invention 4 | Bifendate+CCl 4 | Blank |
| Average Ridit value | 0.50 | 0.65 | 0.37 | 1.0 |
| The fiducial limit scope | 0.31～0.69 | 0.45～0.85 | 0.18～0.56 | 0.81～1.19 |
| Compare (P) with the carbon tetrachloride group | ＞0.05 | ＞0.05 | ＜0.05 |
Presentation of results: medicine of the present invention does not see that to inflammatory cell infiltration and cellular fat change antagonism is arranged for by the downright bad effect of the mouse liver cell due to the carbon tetrachloride.
Four, immunoregulation effect
1, to the regulating action of normal white mice immune organ thymus nature atrophy: get white mice body weight 20～22 grams, male and female half and half, irritate stomach for normal saline 20ml/kg first group of every day, irritate stomach for second group and give medicinal granule 20g/kg of the present invention, irritate stomach for the 3rd group and give medicinal granule 4.4g/kg of the present invention, each organizes equal successive administration six days, cutd open in the 7th day and get thymus and weigh, with the per 100 gram numbers that restrain the thymus of Mus is index, and difference degree of each group of statistics sees Table 9.
The influence of table 9 pair mouse thymus atrophy
| Group | Dosage | Number of animals | Thymus is heavy | P |
| The normal saline group | 20ml/kg | 29 | 0.27±0.04 | |
| The administration group | 20g/kg | 10 | 0.41±0.12 | ＜0.01 |
| The administration group | 4.4g/kg | 19 | 0.40±0.11 | ＜0.01 |
Result of the test shows, thymus natural atrophy of normal white mice along with the reduction of immunologic function, and the granule of Chinese medicine of the present invention can resist this atrophy, shows immunoregulation effect.
2, to the influence of immature white mouse immune organ thymus
Taking out the immature white mouse male and female of giving birth to 21 days does not limit, body weight 9～11 grams, evenly be divided into two groups, 15 every group, the granule solution of the medicine of the present invention of one group every subcutaneous injection 2.2mg/kg, second group every day subcutaneous injection normal saline 0.1ml/ only, all successive administration is three days, gets thymus, and weighs in the 4th day, thymic weight (gram number) with per 100 gram Mus body weight is an index, adds up the difference between two groups.The results are shown in Table 10
The influence of table 10 pair immature white mouse atrophy of thymus gland
| Group | Dosage | Number of animals | Thymus is heavy | P |
| The normal saline group | 10ml/kg | 15 | 0.40±0.14 | |
| The administration group | 2.2g/kg | 15 | 0.31±0.13 | ＞0.05 |
The result shows that the granule of Chinese medicine of the present invention has not showed the atrophy effect to immature white mouse thymus.
The clinical observation of the chronic chronic hepatitis of Drug therapy of the present invention is as follows:
This tests the granule of used medicine for Chinese medicine of the present invention.
One, case choice criteria
Allly meet following three being in hospital or clinic case, all can be used as the clinical research observation object
A) history of virus hepatitis surpasses half a year, still has liver function injury at present, about the chronic hepatitis diagnostic criteria, meets the diagnosis of chronic persistent hepatitis (CPH) or chronic active hepatitis (CAH) according to " viral hepatitis is prevented and treated scheme ".
B) the HBsAg positive and the HBeAg positive.
C) glutamate pyruvate transaminase (ALT) or thymol turbidity test (TTT) are unusual.
Following disease should be as the case of clinical observation: (1) toxic hepatitis.(2) alcoholic liver disease.(3) liver cirrhosis due to the various diseases.(4) schistosomicide hepatopathy.(5) liver tumor (comprising hepatocarcinoma).
Two, general clinical data
According to above-mentioned case choice criteria, selected case is assigned as observation group's 354 examples immediately in 3: 1: 1 ratio, contrast one, two group 100 examples.
Observation group's 354 examples, male 278 examples, women 76 examples; The oldest 66, minimum 3 years old, average 33.47 years old; The course of disease is the longest 324 months, minimum June, average 32.05 months; Chronic persistent hepatitis 215 examples, chronic active hepatitis 139 examples; The average 203.9IU/L of ALT value; The average 12.3u of TTT value, clinic case 156 examples, inpatient's 198 examples.
The general clinical data of two matched groups is similar substantially to observation group, sees table one, table two for details.
General clinical material contrast between one group of table one, observation group and the contrast
General clinical material contrast between two groups of table two, observation group and the contrasts
Find out that from table one, table two between observation group and two matched groups, condition is equal to substantially, and comparability is arranged.
Three, Therapeutic Method:
1, observation group: all by Chinese medical discrimination belong to stagnation of liver-QI with deficiency of the spleen, wet resistance sun is held back card, card is seen: hypochondriac pain abdominal distention, feeling of fullness is indigestion and loss of appetite, body is tired weak, big loose stool is thin, pale tongue is dark, tongue body is swollen or indentation, thin white fur of tongue or white greasy, deep and stringy pulse or deep and slow case arranged.Give the granule of medicine of the present invention.Be grown up each 2 bags (adorning 10 grams in every bag), every day three times, boiled water is taken after mixing it with water, and child dose cuts down according to the circumstance.Three months courses of treatment, but the course of treatment completely the back patient agree proper extension course of treatment medicine time to two.Do not obey the other treatment hepatitis medicament during the treatment in addition
2, contrast is one group: use vitamin C, each 0.1 gram, three times on the one; Mixed vitamin B, each 2, three times on the one; Liver honor, each 2, three times on the one; Three months is a course of treatment.
3, contrast is two groups: use Sophora Tankinensis, and each 4 milliliters, intramuscular injection, once-a-day, three months is a course of treatment.
Four, clinical observation project:
1, all by traditional Chinese medical science four diagnostic methods requirement detailed medical history-taking, symptom is carried out inspections such as tongue, arteries and veins, liver, spleen.
2, get blood before the treatment beginning and do once, comprise ALT, TTT, HBsAg, HBeAg etc. at least than more comprehensive laboratory examination, have the case of jaundice to add to survey icteric index and the red matter of serum gallbladder quantitative.
Also should strive for detecting as anti--HBs, anti--HBe, anti--HBc, DNA-P, HBV-DNA etc. about other indexs of hepatitis B.
Other are checked according to state of an illness needs and may select survey (as amynologic index, Archon protein determination, protein electrophoresis, cholesterol determination, B ultrasonic and liver are worn biopsy etc.).
3, treatment beginning back liver function and HBsAg, HBeAg checked once in principle in every month.
4, some cases adds survey blood, urine, just conventional, electrocardiogram, and renal function (BUN) treatment front and back are respectively once.
5, follow up a case by regular visits to: the case that treatment finishes, strive for follow-up observation 3 months or longer, and results such as 1-2 liver function and HBsAg, HBeAg check are arranged.
Five, curative effect determinate standard
With reference to the novel drugs curative effect level Four overall merit standard in " the clinical research guideline of treatment by Chinese herbs viral hepatitis ", efficacy determination following (adding up respectively) by chronic persistent hepatitis and chronic active hepatitis:
1, recent clinical cure index:
A, cardinal symptom disappear;
B, hepatosplenomegaly disappear or retraction, and the hepatic region does not have obvious tenderness and kowtows pain;
C, the every inspection of liver function have all recovered normal;
D, hepatitis B replication index are not done requirement.
2, produce effects standard:
A, cardinal symptom disappear substantially;
B, hepatosplenomegaly retraction, the hepatic region has not had obvious tenderness and has kowtowed pain;
The preceding unusual project of c, liver function test and HBVM treatment has more than three replys normally.
3, effective standard:
A, cardinal symptom are obviously improved or are disappeared;
B, hepatosplenomegaly bounce back or stablize no change;
There have binomial to reply in the unusual project before c, liver function test and the HBVM treatment to be normal.
4, invalid: as not reach above-mentioned standard person
Six, therapeutic outcome
(1) total effective rate analysis:
The recent clinical cure rate 37% of observation group, with 4% comparing of two groups of 0% and contrasts of one group of contrast, and the total effective rate 66.95% of observation group and one group of contrast 21% and contrast two groups 39% compare, the blood processing all has the difference of highly significant by statistics.See table three for details.
Table three is respectively organized total effective rate relatively
*Compare with observation group P＜0.01
(2) doing well,improving and disappearance situation
Table four observation group doing well,improving and disappearance situation
The situation of improving and disappearing from this group case main clinic symptoms, for stagnation of liver-QI with deficiency of the spleen, the symptom effect of having clear improvement due to wet resistance sun is held back.
(3) chronic persistent hepatitis, chronic active hepatitis efficacy analysis statistics:
1, the chronic persistent hepatitis total effective rate is analyzed:
The recent clinical cure rate 43.70% of observation group and one group of contrast 0% and contrast two groups 2.27% compare, and 29.55% the comparing of two groups of 13.33% and contrasts of the total effective rate 69.77% of observation group and one group of contrast, learn the difference that processing all has highly significant by statistics.See table five for details.
Table five chronic persistent hepatitis is respectively organized total effective rate relatively
* compare with observation group P＜0.01
2, the chronic active hepatitis total effective rate relatively
The recent clinical cure rate 27.34% of observation group, with 5.36% comparing of two groups of 0% and contrasts of one group of contrast, and the total effective rate 62.59% of observation group compares with 27% of one group of contrast, learns processing by statistics, and the difference of highly significant is all arranged; Compare P＞0.05, there was no significant difference with 46.43% of two groups of contrasts.See table six for details.
Table six chronic active hepatitis is respectively organized total effective rate relatively
* P＜0.01
*Compare with observation group P＞0.05
(4) HBVM is influenced
1, the cloudy commentaries on classics situation of HBsAg
1% comparing of two groups of 0% and contrasts of the negative conversion rate 12.99% of observation group and one group of contrast learned the difference that processing all has highly significant by statistics.The HBsAg negative conversion rate of this group case is apparently higher than the natural negative conversion rate of domestic and foreign literature report.See table seven for details.
Respectively organize the HBsAg negative conversion rate relatively after table seven treatment
| Positive routine number before the treatment | The routine number of the cloudy commentaries on classics in treatment back | Negative conversion rate (%) | |
| Observation group | 354 | 46 | 12.99 |
| Contrast one group | 100 | 0 | 0* |
| Contrast two groups | 100 | 1 | 1.00* |
* compare with observation group P＜0.01
2, to the cloudy influence of changeing and being converted to anti--HBe of HBeAg
(1) the cloudy commentaries on classics situation of HBeAg
The negative conversion rate 49.15% of observation group with 24% comparing of two groups of 2% and contrasts of one group of contrast, is learned the difference that processing all has highly significant by statistics.The HBeAg negative conversion rate of this group case is apparently higher than the natural negative conversion rate (11%) of reported literature.See table eight for details.
Respectively organize the HBeAg negative conversion rate relatively after table eight treatment
| Positive routine number before the treatment | The routine number of the cloudy commentaries on classics in treatment back | Negative conversion rate (%) | |
| Observation group | 354 | 174 | 49.15 |
| Contrast one group | 100 | 2 | 2.00* |
| Contrast two groups | 100 | 24 | 24.00* |
* compare with observation group P＜0.01
(2) the cloudy commentaries on classics situation of the HBeAg of recent clinical cure case
Recent clinical cure 132 examples of observation group (all the HBeAg positive), cloudy 83 examples of changeing of treatment back HBeAg, negative conversion rate 63% shows the case of recent clinical cure, hepatitis B virus duplication index great majority are under control.Because contrast does not have recent clinical cure case for one group, contrasts only 4 examples of two groups of recent clinical cure cases, so the analysis that do not take statistics.
(3) HBeAg is converted to the situation of anti--HBe:
The conversion ratio 16.95% of observation group is compared with 2% of one group of contrast, learns by statistics and handles, and has the difference of highly significant to compare P value＞0.05, there was no significant difference with 10% of two groups of contrasts.See table nine for details.
Respectively organize the conversion ratio comparison that HBeAg is converted to anti--HBe after table nine treatment
| The positive routine number of HBeAg before the treatment | Be converted to anti--HBe example number after the treatment | Conversion ratio (%) | |
| Observation group | 354 | 60 | 16.95 |
| Contrast one group | 100 | 2 | 2.00* |
| Contrast two groups | 100 | 10 | 10.00** |
* compare with observation group P＜0.01 * * P＞0.05
3, to the influence of DNA-P
This detection is not done requirement in the case choice criteria, only done partly and worked, and from statistics certain significance for reference is arranged.See table ten for details.
Respectively organize the DNA-P normalization rate relatively after table ten treatment
| Before the treatment＞25 routine numbers | Treatment back＜25 routine numbers | Normalization rate (%) | |
| Observation group | 37 | 19 | 51.35 |
| Contrast one group | 67 | 5 | 7.46* |
| Contrast two groups | 62 | 15 | 24.19 |
* compare with observation group P＜0.01
4, the cloudy commentaries on classics situation of HBV-DNA
This detection is not done requirement in the case choice criteria, only done partly and worked, and from statistics certain significance for reference is arranged.See table ten one for details.
The negative conversion rate of respectively organizing HBV-DNA after table ten treatment compares
| Positive routine number before the treatment | The routine number of the cloudy commentaries on classics in treatment back | Negative conversion rate (%) | |
| Observation group | 17 | 7 | 41.18 |
| Contrast one group | 63 | 9 | 14.28 |
| Contrast two groups | 51 | 12 | 23.53 |
Medication before and after look blood, urine, just routine and electrocardiogram, all no abnormal change of renal function, B ultrasonic.
Chinese medicine preparation of the present invention is through clinical experimental study, prove that recent clinical cure rate and total effective rate are all apparently higher than one group of contrast (general hepatoprotective) and two groups (Sophora Tankinensis) of contrast, P value＜0.01, and suppressing obviously to be better than two matched groups aspect the hepatitis B virus duplication, the P value is all＜0.01.Illustrate that Chinese medicine preparation of the present invention is to belong to " stagnation of liver-QI with deficiency of the spleen, wet resistance sun are held back " the very satisfied medicine of card person curative effect in the treatment chronic hepatitis.
Show according to clinical and data experimentation, form the Chinese medicine of Chinese medicine preparation of the present invention, have the function of the turbid descending, blood fat reducing, regulation and control immunity and inhibition virus replication respectively.Medicine of the present invention proves and can obviously reduce toxicity and the lethal effect of carbon tetrachloride to mice through drug efficacy study, can significantly reduce by the Glutamate pyruvate transaminase rises due to the carbon tetrachloride, and the turbid descending is also had effect.Laboratory animal hepatic tissue microscopically is observed, and hepatic necrosis degree administration group obviously alleviates than not administration group.Hepatocyte fatty range degree administration group not administration of liquor ratio group alleviates.Medicine of the present invention can stimulate the thymus growth and have anti-atrophy effect.Thymus is immune maincenter, so medicine of the present invention has potentiation to immunologic function.Medication before and after look blood, urine, just routine and electrocardiogram, all no abnormal change of renal function, B ultrasonic proves that medicine of the present invention is a safety non-toxic.
The specific embodiment
Embodiment 1
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 20 Fructus Aurantiis 20 Radix Paeoniae Albas 30 Folium Citri tangerinae 20
Radix Salviae Miltiorrhizae 30 Radixs Astragali 40 Radix Codonopsis 24 Ramulus Cinnamomi 10
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 30 Rhizoma Pinelliae Preparatum 24
Rhizoma Coptidis 10 Semen Cassiaes 30 Fructus Crataegis 30 Fructus Schisandrae Chinensis 20
Make Chinese medicine preparation according to a conventional method.
The weight portion proportioning of above-mentioned raw materials is also preferred:
Embodiment 2
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 10 Fructus Aurantiis 30 Radix Paeoniae Albas 20 Folium Citri tangerinae 15
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 15 Ramulus Cinnamomi 5
Poria 40 Radix Et Caulis Acanthopanacis Senticosis 40 Fructus Trichosanthis 20 Rhizoma Pinelliae Preparatum 30
Rhizoma Coptidis 6 Semen Cassiaes 30 Fructus Crataegis 35 Fructus Schisandrae Chinensis 30.
Preparation method is as follows: above ten Six-elements, and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby.Fructus Schisandrae Chinensis is pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water secondary, and each 1 hour, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and dextrin, Icing Sugar is an amount of, granulates, and granulate, packing, promptly.
Embodiment 3
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 30 Fructus Aurantiis 10 Radix Paeoniae Albas 40 Folium Citri tangerinae 30
Radix Salviae Miltiorrhizae 20 Radixs Astragali 30 Radix Codonopsis 35 Ramulus Cinnamomi 5
Poria 20 Radix Et Caulis Acanthopanacis Senticosis 20 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 15 Semen Cassiaes 20 Fructus Crataegis 20 Fructus Schisandrae Chinensis 10.
Preparation method is as follows: above ten Six-elements, and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby.Fructus Schisandrae Chinensis is pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water secondary, and each 1.5 hours, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and dextrin, pill, promptly.
Embodiment 4
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 25 Fructus Aurantiis 20 Radix Paeoniae Albas 25 Folium Citri tangerinae 10
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 20 Ramulus Cinnamomi 15
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 10 Semen Cassiaes 40 Fructus Crataegis 40 Fructus Schisandrae Chinensis 10.
Preparation method is as follows: above ten Six-elements, and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby.Fructus Schisandrae Chinensis is pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water three times, and each 0.5 hour, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and dextrin drying, capsule charge, promptly.
Embodiment 5
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 25 Fructus Aurantiis 20 Radix Paeoniae Albas 25 Folium Citri tangerinae 10
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 20 Ramulus Cinnamomi 15
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 10 Semen Cassiaes 40 Fructus Crataegis 40 Fructus Schisandrae Chinensis 10.
Preparation method is as follows: above ten Six-elements, and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby.Fructus Schisandrae Chinensis is pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water secondary, and each 3 hours, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder, granulates, and adds magnesium stearate, tabletting, and coating, promptly.
Embodiment 6
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 20 Fructus Aurantiis 20 Radix Paeoniae Albas 30 Folium Citri tangerinae 20
Radix Salviae Miltiorrhizae 30 Radixs Astragali 40 Radix Codonopsis 24 Ramulus Cinnamomi 10
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 30 Rhizoma Pinelliae Preparatum 24
Rhizoma Coptidis 10 Semen Cassiaes 30 Fructus Crataegis 30 Fructus Schisandrae Chinensis 20
Preparation method is as follows: above ten Six-elements, Fructus Schisandrae Chinensis are pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.Ten five tastes such as all the other Radix Bupleuri decoct with water secondary, and each 2 hours, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, and qinghuo reagent adds an amount of dextrin and aspartame, granulate, granulate, packing is promptly.
Embodiment 7
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 10 Fructus Aurantiis 30 Radix Paeoniae Albas 20 Folium Citri tangerinae 15
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 15 Ramulus Cinnamomi 5
Poria 40 Radix Et Caulis Acanthopanacis Senticosis 40 Fructus Trichosanthis 20 Rhizoma Pinelliae Preparatum 30
Rhizoma Coptidis 6 Semen Cassiaes 30 Fructus Crataegis 35 Fructus Schisandrae Chinensis 30.
Preparation method is as follows: above ten Six-elements, Fructus Schisandrae Chinensis are pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.Ten five tastes such as all the other Radix Bupleuri decoct with water three times, and each 1 hour, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, qinghuo reagent adds an amount of dextrin, pill, packing, promptly.
Embodiment 8
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 30 Fructus Aurantiis 10 Radix Paeoniae Albas 40 Folium Citri tangerinae 30
Radix Salviae Miltiorrhizae 20 Radixs Astragali 30 Radix Codonopsis 35 Ramulus Cinnamomi 5
Poria 20 Radix Et Caulis Acanthopanacis Senticosis 20 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 15 Semen Cassiaes 20 Fructus Crataegis 20 Fructus Schisandrae Chinensis 10.
Preparation method is as follows: above ten Six-elements, Fructus Schisandrae Chinensis are pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.Ten five tastes such as all the other Radix Bupleuri decoct with water secondary, and each 1 hour, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, and qinghuo reagent adds an amount of dextrin, the system piller, drying, capsule charge, promptly.
Embodiment 9
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 20 Fructus Aurantiis 20 Radix Paeoniae Albas 30 Folium Citri tangerinae 20
Radix Salviae Miltiorrhizae 30 Radixs Astragali 40 Radix Codonopsis 24 Ramulus Cinnamomi 10
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 30 Rhizoma Pinelliae Preparatum 24
Rhizoma Coptidis 10 Semen Cassiaes 30 Fructus Crataegis 30 Fructus Schisandrae Chinensis 20
Preparation method is as follows: above ten Six-elements, Fructus Schisandrae Chinensis are pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.Ten five tastes such as all the other Radix Bupleuri decoct with water three times, and each 0.5 hour, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, qinghuo reagent adds microcrystalline Cellulose, crosslinked poly-carmethose is granulated, and granulate adds magnesium stearate, little confused silica gel again, tabletting, promptly.
Embodiment 10
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 30 Fructus Aurantiis 10 Radix Paeoniae Albas 40 Folium Citri tangerinae 30
Radix Salviae Miltiorrhizae 20 Radixs Astragali 30 Radix Codonopsis 35 Ramulus Cinnamomi 5
Poria 20 Radix Et Caulis Acanthopanacis Senticosis 20 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 15 Semen Cassiaes 20 Fructus Crataegis 20 Fructus Schisandrae Chinensis 10.
Preparation method is as follows: above ten Six-elements, Fructus Schisandrae Chinensis are pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.Ten five tastes such as all the other Radix Bupleuri decoct with water secondary, each 2 hours, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, Polyethylene Glycol-6000, ethyl hydroxybenzoate, Oleum Arachidis hypogaeae semen, purified water mix homogeneously with an amount of prepare rubber with gelatin, Polyethylene Glycol-400, glycerol, water, make soft capsule, promptly.
Embodiment 11
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 10 Fructus Aurantiis 30 Radix Paeoniae Albas 20 Folium Citri tangerinae 15
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 15 Ramulus Cinnamomi 5
Poria 40 Radix Et Caulis Acanthopanacis Senticosis 40 Fructus Trichosanthis 20 Rhizoma Pinelliae Preparatum 30
Rhizoma Coptidis 6 Semen Cassiaes 30 Fructus Crataegis 35 Fructus Schisandrae Chinensis 30.
Preparation method is as follows: above ten Six-elements, after the Fructus Schisandrae Chinensis fragmentation, use carbon dioxide supercritical fluid extraction, extracting pressure: and 21Mpa, temperature: 45 ℃, time: 2.5-3 hour, separation temperature: 50 ℃, pressure: 6Mpa, flow velocity: 47-53kg/h, extracting solution is standby.Ten five tastes such as all the other Radix Bupleuri decoct with water, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, dry and an amount of Polyethylene Glycol-6000, ethyl hydroxybenzoate, Oleum Arachidis hypogaeae semen, purified water, mix homogeneously prepares rubber with gelatin, Polyethylene Glycol-400, glycerol, water, make soft capsule, promptly.
Embodiment 12
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 10 Fructus Aurantiis 30 Radix Paeoniae Albas 20 Folium Citri tangerinae 15
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 15 Ramulus Cinnamomi 5
Poria 40 Radix Et Caulis Acanthopanacis Senticosis 40 Fructus Trichosanthis 20 Rhizoma Pinelliae Preparatum 30
Rhizoma Coptidis 6 Semen Cassiaes 30 Fructus Crataegis 35 Fructus Schisandrae Chinensis 30.
Preparation method is as follows: above ten Six-elements, and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby.After the Fructus Schisandrae Chinensis fragmentation, use carbon dioxide supercritical fluid extraction, extracting pressure: 21Mpa, temperature: 45 ℃, time: 2.5-3 hour, separation temperature: 50 ℃, pressure: 6Mpa, flow velocity: 47-53kg/h, extracting solution is standby.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water three times, and each 0.5 hour, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and dextrin and granulates, capsule charge, promptly.
Embodiment 13
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 25 Fructus Aurantiis 20 Radix Paeoniae Albas 25 Folium Citri tangerinae 10
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 20 Ramulus Cinnamomi 15
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 10 Semen Cassiaes 40 Fructus Crataegis 40 Fructus Schisandrae Chinensis 10.
Preparation method is as follows: above ten Six-elements, and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby.Fructus Schisandrae Chinensis is pulverized back 80% alcohol reflux, and it is standby that extracting solution reclaims ethanol.The coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water three times, and each 0.5 hour, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste.Qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and dextrin system piller, capsule charge, promptly.
Embodiment 14
Radix Bupleuri or Radix Bupleuri (processed with vinegar) 20 Fructus Aurantiis 20 Radix Paeoniae Albas 30 Folium Citri tangerinae 20
Radix Salviae Miltiorrhizae 30 Radixs Astragali 40 Radix Codonopsis 24 Ramulus Cinnamomi 10
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 30 Rhizoma Pinelliae Preparatum 24
Rhizoma Coptidis 10 Semen Cassiaes 30 Fructus Crataegis 30 Fructus Schisandrae Chinensis 20.
Preparation method is as follows: above ten Six-elements, after the Fructus Schisandrae Chinensis fragmentation, use carbon dioxide supercritical fluid extraction, extracting pressure: and 21Mpa, temperature: 45 ℃, time: 2.5-3 hour, separation temperature: 50 ℃, pressure: 6Mpa, flow velocity: 47-53kg/h, extracting solution is standby.Ten five tastes such as all the other Radix Bupleuri decoct with water secondary, and each 1 hour, collecting decoction, centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, and qinghuo reagent adds an amount of dextrin, granulates, drying, capsule charge, promptly.
Claims (21)
1. Chinese medicine for the treatment of chronic hepatitis is characterized in that it is prepared from by acceptable auxiliary on following weight parts proportion raw material medicine and the pharmaceutics:
Radix Bupleuri 10～30 Fructus Aurantiis 10～30 Radix Paeoniae Albas 20～40 Folium Citri tangerinae 10～30
Radix Salviae Miltiorrhizae 20～40 Radixs Astragali 25～55 Radix Codonopsis 15～35 Ramulus Cinnamomi 5～15
Poria 20～40 Radix Et Caulis Acanthopanacis Senticosis 20～40 Fructus Trichosanthis 20～40 Rhizoma Pinelliae Preparatum 16～32
Rhizoma Coptidis 5～15 Semen Cassiaes 20～40 Fructus Crataegis 20～40 Fructus Schisandrae Chinensis 10～30.
2. Chinese medicine according to claim 1 is characterized in that the weight portion of crude drug is:
Radix Bupleuri 13.33～26.67 Fructus Aurantiis 13.33～26.67 Radix Paeoniae Albas 20～40 Folium Citri tangerinae 13.33～26.67
Radix Salviae Miltiorrhizae 20～40 Radixs Astragali 26.67～53.33 Radix Codonopsis 16～32 Ramulus Cinnamomi 6.67～13.33
Poria 20～40 Radix Et Caulis Acanthopanacis Senticosis 20～40 Fructus Trichosanthis 20～40 Rhizoma Pinelliae Preparatum 16～32
Rhizoma Coptidis 6.67～13.33 Semen Cassiaes 20～40 Fructus Crataegis 20～40 Fructus Schisandrae Chinensis 13.33～26.67.
3. Chinese medicine according to claim 1 is characterized in that the weight portion of crude drug is:
Radix Bupleuri 15～25 Fructus Aurantiis 15～25 Radix Paeoniae Albas 25～35 Folium Citri tangerinae 15～25
Radix Salviae Miltiorrhizae 25～35 Radixs Astragali 30～50 Radix Codonopsis 20～30 Ramulus Cinnamomi 8～12
Poria 15～35 Radix Et Caulis Acanthopanacis Senticosis 25～35 Fructus Trichosanthis 25～35 Rhizoma Pinelliae Preparatum 20～30
Rhizoma Coptidis 8～12 Semen Cassiaes 25～35 Fructus Crataegis 25～35 Fructus Schisandrae Chinensis 15～25.
4. Chinese medicine according to claim 1 is characterized in that the weight portion of crude drug is:
Radix Bupleuri 10 Fructus Aurantiis 30 Radix Paeoniae Albas 20 Folium Citri tangerinae 15
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 15 Ramulus Cinnamomi 5
Poria 40 Radix Et Caulis Acanthopanacis Senticosis 40 Fructus Trichosanthis 20 Rhizoma Pinelliae Preparatum 30
Rhizoma Coptidis 6 Semen Cassiaes 30 Fructus Crataegis 35 Fructus Schisandrae Chinensis 30.
5. Chinese medicine according to claim 1 is characterized in that the weight portion of crude drug is:
Radix Bupleuri 30 Fructus Aurantiis 10 Radix Paeoniae Albas 40 Folium Citri tangerinae 30
Radix Salviae Miltiorrhizae 20 Radixs Astragali 30 Radix Codonopsis 35 Ramulus Cinnamomi 5
Poria 20 Radix Et Caulis Acanthopanacis Senticosis 20 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 15 Semen Cassiaes 20 Fructus Crataegis 20 Fructus Schisandrae Chinensis 10.
6. Chinese medicine according to claim 1 is characterized in that the weight portion of crude drug is:
Radix Bupleuri 25 Fructus Aurantiis 20 Chinese herbaceous peonies 25 Folium Citri tangerinae 10
Radix Salviae Miltiorrhizae 40 Radixs Astragali 55 Radix Codonopsis 20 Ramulus Cinnamomi 15
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 40 Rhizoma Pinelliae Preparatum 15
Rhizoma Coptidis 10 Semen Cassiaes 40 Fructus Crataegis 40 Fructus Schisandrae Chinensis 10.
7. Chinese medicine according to claim 1 is characterized in that the weight portion of crude drug is:
Radix Bupleuri 20 Fructus Aurantiis 20 Radix Paeoniae Albas 30 Folium Citri tangerinae 20
Radix Salviae Miltiorrhizae 30 Radixs Astragali 40 Radix Codonopsis 24 Ramulus Cinnamomi 10
Poria 30 Radix Et Caulis Acanthopanacis Senticosis 30 Fructus Trichosanthis 30 Rhizoma Pinelliae Preparatum 24
Rhizoma Coptidis 10 Semen Cassiaes 30 Fructus Crataegis 30 Fructus Schisandrae Chinensis 20.
8. Chinese medicine according to claim 1 is characterized in that Radix Bupleuri wherein is Radix Bupleuri (processed with vinegar).
9. according to the arbitrary described Chinese medicine of claim 1-8, it is characterized in that: adjuvant wherein is starch, lactose, sucrose, dextrin, betacyclodextrin, magnesium stearate, Pulvis Talci, aspartame, cyclamate, stevioside, crosslinked polyethylene pyrrole Lip river alkane ketone, crosslinked poly-carmethose, micropowder silica gel, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, gelatin, Polyethylene Glycol-400, Polyethylene Glycol-6000, glycerol, ethyl hydroxybenzoate, vegetable oil, or in the hydrogenated vegetable oil one or more.
10. according to the arbitrary described Chinese medicine of claim 1-8, it is characterized in that: this Chinese medicine is granule, pill, hard capsule, soft capsule, tablet or dispersible tablet.
11. preparation method of Chinese medicine according to claim 10 is characterized in that the preparation method of granule comprises the following steps:
(1) above ten Six-elements, the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby;
(2) with 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized;
(3) coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water, and collecting decoction is centrifugal, gets centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merges, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste;
(4) qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and adjuvant, granulates, and granulate, promptly.
12. preparation method of Chinese medicine according to claim 10 is characterized in that the preparation method of pill comprises the following steps:
(1) above ten Six-elements, the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby, and with 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized;
(2) coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water, and collecting decoction is centrifugal, gets centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merges, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste;
(3) qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and adjuvant, pill, promptly.
13. preparation method of Chinese medicine according to claim 10 is characterized in that the preparation method of capsule comprises the following steps:
(1) above ten Six-elements, the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby;
(2) with 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized;
(3) coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water, and collecting decoction is centrifugal, gets centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merges, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste;
(4) qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and adjuvant granulation or system piller, drying, and capsule charge, promptly.
14. preparation method of Chinese medicine according to claim 10 is characterized in that the preparation method of tablet comprises the following steps:
(1) above ten Six-elements, the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum are ground into fine powder, sieve, mixing, its coarse powder is standby;
(2) with 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized;
(3) coarse powder of 12 flavors such as all the other Radix Bupleuri and the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum decocts with water, and collecting decoction is centrifugal, gets centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merges, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste;
(4) qinghuo reagent adds the Radix Paeoniae Alba, Poria, Rhizoma Pinelliae Preparatum fine powder and adjuvant, granulates, and tabletting, promptly.
15. preparation method of Chinese medicine according to claim 10 is characterized in that the preparation method of granule comprises the following steps:
(1) above ten Six-elements, with 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized;
(2) ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, and qinghuo reagent adds adjuvant, granulates, promptly.
16. preparation method of Chinese medicine according to claim 10 is characterized in that the preparation method of pill comprises the following steps:
(1) above ten Six-elements, with 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized;
(2) ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, and qinghuo reagent adds adjuvant, pill, promptly.
17. preparation method of Chinese medicine according to claim 10 is characterized in that the preparation method of capsule comprises the following steps:
(1) above ten Six-elements, with 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized;
(2) ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, granulate or the system piller, and drying, capsule charge, promptly.
18. preparation method of Chinese medicine according to claim 10 is characterized in that the preparation method of dispersible tablet comprises the following steps:
(1) above ten Six-elements, with 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized;
(2) ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, and qinghuo reagent adds adjuvant, granulates, granulate, tabletting, promptly.
19. preparation method of Chinese medicine according to claim 10 is characterized in that the preparation of soft capsule method comprises the following steps:
(1) above ten Six-elements, with 60～90% alcohol reflux, it is standby that extracting solution reclaims ethanol after Fructus Schisandrae Chinensis was pulverized;
(2) ten five tastes such as all the other Radix Bupleuri decoct with water, and collecting decoction is centrifugal, get centrifugal medicinal liquid and Fructus Schisandrae Chinensis medicinal liquid and merge, and being concentrated into 50 ℃, to survey relative densities be 1.10～1.30 clear paste, drying, and qinghuo reagent adds adjuvant, makes soft capsule, promptly.
20. according to the described preparation method of Chinese medicine of claim 11～19, it is characterized in that wherein Fructus Schisandrae Chinensis can be used as following step process: after the Fructus Schisandrae Chinensis fragmentation, use carbon dioxide supercritical fluid extraction, extracting pressure: 18～25Mpa, temperature: 40～50 ℃, the time: 1～4 hour, separation temperature: 40～55 ℃, pressure: 6～8Mpa, flow velocity: 45-55kg/h, extracting solution is standby.
21. the application of the arbitrary described Chinese medicine of claim 1-8 in the medicine of preparation treatment chronic hepatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100759135A CN100382824C (en) | 2006-04-24 | 2006-04-24 | Chinese traditional medicine for treating chronic hepatitis, and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100759135A CN100382824C (en) | 2006-04-24 | 2006-04-24 | Chinese traditional medicine for treating chronic hepatitis, and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1872258A CN1872258A (en) | 2006-12-06 |
| CN100382824C true CN100382824C (en) | 2008-04-23 |
Family
ID=37482967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100759135A Active CN100382824C (en) | 2006-04-24 | 2006-04-24 | Chinese traditional medicine for treating chronic hepatitis, and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100382824C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101112613B (en) * | 2007-08-07 | 2011-09-21 | 邵明伦 | Medicine for treating cholecystitis, gastritis and hepatitis and method for preparing the same |
| CN102836388B (en) * | 2012-08-25 | 2014-01-08 | 李新欣 | Traditional Chinese medicine for chronic hepatitis treatment |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1112834A (en) * | 1994-08-29 | 1995-12-06 | 郭约翰 | Oral liquid for curing hepatitis B, and method for prodn. of same |
| CN1280841A (en) * | 1999-07-01 | 2001-01-24 | 陶杰 | Medicine for treating hepatitis B and rheumatoid diseases |
-
2006
- 2006-04-24 CN CNB2006100759135A patent/CN100382824C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1112834A (en) * | 1994-08-29 | 1995-12-06 | 郭约翰 | Oral liquid for curing hepatitis B, and method for prodn. of same |
| CN1280841A (en) * | 1999-07-01 | 2001-01-24 | 陶杰 | Medicine for treating hepatitis B and rheumatoid diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1872258A (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101332284B (en) | Chinese traditional medicine composition for treating ulcerative colitis and its preparation method | |
| CN105148258A (en) | Composition and application thereof, and preparation containing composition | |
| CN102210836A (en) | Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer | |
| CN102600368B (en) | Pharmaceutical composition, as well as preparation method and application thereof | |
| CN101007080A (en) | Chinese medicinal preparation for lowering blood fat and benefiting liver | |
| CN102727687A (en) | Medicine treating chronic fatigue syndrome and its application | |
| CN100382824C (en) | Chinese traditional medicine for treating chronic hepatitis, and preparation method | |
| CN102178786B (en) | Medicament combination for treating diabetic peripheral neuropathy as well as preparation method and application thereof | |
| CN101810671B (en) | Chinese medicinal preparation for treating AIDS and preparation method thereof | |
| CN101940758B (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and application thereof | |
| CN101695562B (en) | Chinese medicinal composition for treating viral hepatitis and preparation method thereof | |
| CN101062374B (en) | Method for preparing Chinese traditional combination capsule for treating cancer and the product thereof | |
| CN111375035B (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN101099852B (en) | Traditional Chinese medicine composition for treating chronic viral hepatitis and preparation method thereof | |
| CN102362993B (en) | Chinese medicinal preparation with effects of protecting intestines and removing toxic materials, and preparation method thereof | |
| CN100471488C (en) | Chinese medicine composition for transquilizing, warming Yang, benefiting Qi and nourishing heart and its prepn | |
| CN100382818C (en) | Prepn process of Chinese medicine and its coated tablet for treating cystic mastoproliferation and mastitis | |
| CN101011470A (en) | Traditional Chinese medicine compound composition for treating hepatitis | |
| CN1733199A (en) | Liver-protecting detoxification particles for curing drug induced liver injury and its production method | |
| CN109091645A (en) | A kind of pharmaceutical composition with treatment inhibition of HIV | |
| CN102935151B (en) | Medicine composition for protecting liver and lowering transaminase and preparation method and application thereof | |
| CN107823487B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
| CN102406869B (en) | Intestine-protecting and detoxifying micro pellets and use thereof | |
| CN1333044A (en) | Wasting-thirst hypoglycemic preparation | |
| CN101897752B (en) | Chinese medicinal composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: LIAONING HUARUN BENXI SANYAO CO., LTD. Free format text: FORMER NAME: LIAONING BENXI SANYAO CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 117004 medicine Park, Benxi economic and Technological Development Zone, Liaoning Patentee after: Liaoning Huarun Benxi Sanyao Co., Ltd. Patentee after: Wang Yongyan Patentee after: Benxi national proprietary Chinese Medicine Engineering Technology Research Center Address before: 117004 medicine Park, Benxi economic and Technological Development Zone, Liaoning Patentee before: Liaoning Benxi Third Pharmaceutical Co., Ltd. Patentee before: Wang Yongyan Patentee before: Benxi national proprietary Chinese Medicine Engineering Technology Research Center |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 117004 medicine Park, Benxi economic and Technological Development Zone, Liaoning Co-patentee after: Wang Yongyan Patentee after: Liaoning Huarun Benxi Sanyao Co., Ltd. Co-patentee after: Benxi National Chinese Patent Medicine Engineering Technology Research Center Co., Ltd. Address before: 117004 medicine Park, Benxi economic and Technological Development Zone, Liaoning Co-patentee before: Wang Yongyan Patentee before: Liaoning Huarun Benxi Sanyao Co., Ltd. Co-patentee before: Benxi National Engineering and Technology Research Center of Chinese Patent Medicine |